Abstract | BACKGROUND: METHODS: In this randomized trial 60 CKD patients stage 3b-5 and anemia (Hb levels: 10-12.5 g/dL) were assigned (1:1) to receive low doses of calcitriol (Group Calcitriol) or paricalcitol (Group Paricalcitol) for 6 months. All the patients had normal values of plasma calcium, phosphorus and PTH, a stable iron balance, and normal values of C-Reactive Protein. The primary endpoint was to evaluate the effects of the two treatments on Hb levels; the modifications in 24hr-proteinuria (UProt) were also evaluated. RESULTS: A significant Group x Time interaction effect was observed in the longitudinal analysis of Hb levels (F(1,172)=31.4, p<0.001). Subjects in Paricalcitol experienced a significant monthly increase of Hb levels equal to +0.16 g/dL [95% C.I. 0.10 to +0.22, p<0.001) while in Group Calcitriol, Hb decrease throughout the follow-up with an average monthly rate of -0.10 g/dL (95% C.I.: -0.17 to -0.04, p<0.001). In Group Paricalcitol, UProt was significantly reduced after 6 months [0.35 (0.1-1.2) vs 0.59 (0.2-1.6), p<0.01], whereas no significant difference emerged in Group Calcitriol. Plasma levels of calcium, phosphate, PTH and of inflammation markers remained in the normal range in both groups throughout the study. CONCLUSIONS: Short-term exposure to paricalcitol results in an independent increase in Hb levels, which occurred with no modification of iron balance, inflammatory markers, and PTH plasma concentrations, and was associated with a decrease in UProt. TRIAL REGISTRATION: ClinicalTrials.gov NCT01768351.
|
Authors | Eleonora Riccio, Massimo Sabbatini, Dario Bruzzese, Ivana Capuano, Silvia Migliaccio, Michele Andreucci, Antonio Pisani |
Journal | PloS one
(PLoS One)
Vol. 10
Issue 3
Pg. e0118174
( 2015)
ISSN: 1932-6203 [Electronic] United States |
PMID | 25781618
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Ergocalciferols
- Hemoglobins
- paricalcitol
- C-Reactive Protein
- Calcitriol
|
Topics |
- C-Reactive Protein
(metabolism)
- Calcitriol
(pharmacology, therapeutic use)
- Ergocalciferols
(pharmacology, therapeutic use)
- Female
- Follow-Up Studies
- Hemoglobins
(metabolism)
- Humans
- Male
- Middle Aged
- Renal Insufficiency, Chronic
(drug therapy, metabolism)
- Treatment Outcome
|